Clinical Trial Update: Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BF2.649 for excessive daytime sleepiness in narcolepsy has completed, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Narcolepsy

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: Bioprojet | Conditions: Narcolepsy, Excessive Daytime Sleepiness | Phase 3 | Status: COMPLETED